<DOC>
	<DOCNO>NCT01898221</DOCNO>
	<brief_summary>The broad , long-term objective project evaluate therapeutic value vein Marshall ( VOM ) ethanol infusion add catheter ablation atrial fibrillation ( AF ) . AF common sustain arrhythmia adult , lead cause stroke , disability increase mortality . Catheter ablation - pulmonary vein ( PV ) antral isolation ( PVAI ) - lead cure , best suit paroxysmal AF , ectopic beat arise pulmonary vein show initiate AF . PVAI success lower persistent AF , role cardiac autonomic system , particularly intrinsic cardiac ganglion , increasingly recognize . Expanding ablation lesion include great area leave atrial ( LA ) anatomy marginally improve outcome , also lead increase procedural complexity duration , need repeat procedure , complication atrial flutter , particularly perimitral flutter ( PMF ) . The investigator develop technique perform rapid ablation atrial tissue AF use ethanol infusion vein Marshall ( VOM ) , show : 1 ) Effective , rapid safe tissue ablation LA tissue neighbor LA ridge leave inferior PV ; 2 ) Regional LA vagal denervation reach intrinsic cardiac ganglion ; 3 ) Facilitation cure PMF ablate mitral isthmus . The investigator propose evaluate outcome difference yield VOM ethanol add conventional PVAI . The specific aim : # 1.To ass impact VOM ethanol infusion procedure success add de novo catheter ablation persistent AF . The investigator randomize patient persistent AF undergo first AF ablation standard PVAI vs. combine VOM ethanol infusion plus PVAI ( VOM-PV ) # 2 . To assess impact VOM ethanol infusion add repeat catheter ablation recurrent AF fail ablation . Patients undergo repeat procedure persistent AF fail PVAI randomize either PVAI VOM-PV repeat procedure . End point include freedom symptomatic electrocardiographic AF 12-15 month .</brief_summary>
	<brief_title>Vein Marshall Ethanol Infusion Persistent Atrial Fibrillation</brief_title>
	<detailed_description>Although risk stroke comparable persistent paroxysmal AF , prevalence persistent AF increase dramatically increasing age , thus overall significant cause morbidity mortality . In United States , currently estimate 3.0 million adult AF , number expect double next 25 year . Hospitalizations primary diagnosis AF close half million per year , generate tremendous economic burden health care system . When compare health care cost non-AF control subject , patient AF great annual healthcare cost ( $ 8705 total annual incremental cost ) . On basis current prevalence data , estimate AF lead national incremental health care cost $ 26 billion . Inadequacy pharmacological treatment option persistent AF Management strategy direct heart rate control stroke prevention -mere palliation- rhythm control . It show rhythm control strategy use antiarrhythmic drug offer benefit elderly patient patient heart failure . Most lack benefit rhythm control strategy think due adverse effect suboptimal efficacy antiarrhythmic drug potentially augment mortality . Indeed , preservation normal sinus rhythm associate decreased mortality . Dronedarone , antiarrhythmic drug show improve outcome nonpermanent AF compare placebo , show double mortality , stroke hospitalization heart failure PALLAS study patient permanent . Thus , antiarrhythmic drug remain suboptimal best treatment AF . Shortcomings catheter ablation persistent AF Weak mechanistic rationale : Isolation pulmonary vein ( PVs2 ) adjacent LA ( PV antrum ) accept procedural endpoint , base mechanistic concept atrial extrasystole arise PVs initiate paroxysmal AF . Other , non-PV trigger demonstrated.36 The link PV extra systole AF clear paroxysmal AF , persistent AF , mechanism AF seem relate chronic atrial substrate acute triggers.4 Indeed , intramural reentry posterior LA seem particularly relevant chronic model AF . In persistent AF , procedure evolve , rather simplistically , include additional lesion -besides isolation PVs , variably place posterior wall , LA roof , towards mitral annulus , superior vena cava,44 leave atrial appendage , area complex fractionate atrial electrograms ( CFAE ) may map . This brute force approach simply destroy tissue yield additional success , new procedural target solid mechanistic base need . Suboptimal success need repeat procedure . Despite additional tissue destruction , ablation success persistent AF much low paroxysmal AF , single procedure success report low 27 % , 36 % , 49 % , 61 % 67 % , depend study heterogeneity : definition persistent AF recurrence AF , type AF monitoring , ablation technique operator experience . In order achieve overall acceptable success rate , ( reach 79 % -94 % ) , consistent need repeat procedure ( sometimes 4 ) concomitant use antiarrhythmic drug . The rate repeat procedure experience center reach 70 80 % .PMF catheter ablation persistent AF . Clinical failure first ablation procedure cause , significant portion patient , atrial flutter , rather recurrent AF , recurrence flutter portend great chance success second procedure . Such atrial flutter may cause perimitral reentry 33-60 % patient . Catheter ablation PMF involve creation linear lesion mitral annulus leave inferior PV ( so-called mitral isthmus ) .Achieving complete ablation ( defined bidirectional conduction block across ablation line ) difficult , success rate report 32 % , 64 % , 71 % . It sometimes require ablation inside coronary sinus ( CS ) , close proximity circumflex coronary artery , could damage note , incomplete ablation mitral isthmus proarrhythmogenic , increase risk recurrent flutter 4 time .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>1 . Patients age 21 85 year 2 . Diagnosed symptomatic persistent AF Documentation history AF least 6 month AF spontaneously convert sinus rhythm , persist ≥7 day Sinus rhythm cardioversion NOT exclusion , provide that≥2 episode persistent AF occur previous 6 month 3 . Resistant intolerant least one class I , II , III anti arrhythmic drug ( AAD ) 4 . Patients deem candidate radio frequency ( RF ) ablation AF 5 . Able willing comply pre , post , followup requirement . 1 . Patients previous PVAI procedure leave heart ablation procedure . 2 . Left atrial thrombus . 3 . LA diameter great 65 mm long axis parasternal view , leave atrial volume 200 cc MRI CT. 4 . Left ventricular ejection fraction &lt; 30 % . 5 . Cardiac surgery within previous 180 day . 6 . Expecting cardiac transplantation cardiac surgery within 180 day . 7 . Coronary percutaneous transluminal coronary angioplasty ( PTCA ) /stenting within previous 90 day . 8 . Documented history thrombiembolic event within previous 90 day . 9 . Diagnosed atrial myxoma . 10 . Significant restrictive , constrictive , chronic obstructive pulmonary disease chronic symptom . 11 . Significant congenital anomaly medical problem opinion investigator would preclude enrollment 12 . Women pregnant . 13 . Acute illness active infection time index procedure document either pain , fever , drainage , positive culture and/or leukocytosis ( WBC &gt; 11 . 000 mm3 ) antibiotic prescribe . 14 . Creatinine &gt; 2 . 5 mg/dl ( &gt; 221 μmol/L , except patient dialysis ) . 15 . Unstable angina . 16 . Myocardial infarction within previous 60 day . 17 . History blood clot bleed abnormality . 18 . Contraindication anticoagulation . 19 . Contraindication compute tomography MRI procedure . 20 . Life expectancy less 1 year . 21 . Uncontrolled heart failure . 22 . Presence intramural thrombus , tumor , abnormality precludes catheter introduction positioning . 23 . Presence condition precludes vascular access . 24 . Institute Natural Resources ( INR ) great 3 . 5 within 24 hour procedure . 25 . Can remove antiarrhythmic drug reason AF . 26 . Unwilling unable provide inform consent . 27 . Current report alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>